11月7日,牙科产品制造商登士柏国际(XRAY)在美国股市盘中出现大跌,股价一度重挫逾28%,引发市场哗然。这一大跌与公司下调2024年全年每股收益预期,以及暂停部分产品线销售有关。
根据公司公告,登士柏国际此前预计2024年全年每股收益在1.96至2.02美元,但随后将这一预期下调至1.82至1.86美元。与此同时,公司还自愿暂停了旗下Byte矫正器和印模套件的销售、营销和发货,表示此举是因为正在对与之相关的某些监管要求进行审查。
分析人士认为,登士柏国际业绩预期下调加之部分产品线暂停销售,将对公司今年的收入和利润造成不利冲击,令投资者对其前景产生担忧。尽管公司第三季度营收数据较为乐观,但似乎未能缓解投资者的疑虑情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.